At ASCO 2026, izalontamab brengitecan became the first bispecific antibody-drug conjugate to improve both progression-free and overall survival in triple-negative breast cancer. Inside the EGFRxHER3 mechanism, the Phase 3 trial…
By age seventy, somewhere between ten and twenty percent of people carry a population of mutated blood stem cells that quietly double their risk of heart disease. The condition has…
David Sinclair helped make longevity science impossible to ignore. He also became one of its most contested public figures. Part II examines the criticism, contradictory evidence, and scientific arguments that…
David Sinclair helped move aging research from the scientific margins into mainstream conversation. Through his Harvard lab, his work on sirtuins, NAD+ biology, epigenetic reprogramming, and his public role as…
Harvard researcher Marinka Zitnik is building AI systems designed to uncover hidden treatments for rare and neglected diseases. Her TxGNN work points toward a future where drug repurposing becomes more…
A former Apple and Jawbone engineer built the first FDA-cleared wearable that simultaneously activates muscles and relaxes spasms, giving millions with MS, stroke, cerebral palsy, and spinal cord injuries the…
Zach RobertsSign up for personalized wellness coaching and the Daily Discovery Newsletter.